Mednax, Inc (NYSE:MD) posted its quarterly earnings data on Wednesday. The company reported $0.87 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87, Bloomberg Earnings reports. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. During the same period in the previous year, the firm posted $1.09 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Mednax updated its Q4 guidance to $0.80-0.85 EPS.

TRADEMARK VIOLATION NOTICE: “Mednax, Inc (MD) Announces Quarterly Earnings Results” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/02/mednax-inc-md-announces-quarterly-earnings-results.html.

A number of brokerages recently weighed in on MD. KeyCorp set a $51.00 price objective on shares of Mednax and gave the stock a “buy” rating in a report on Wednesday. BMO Capital Markets began coverage on shares of Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective for the company. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Jefferies Group LLC restated a “hold” rating and issued a $46.00 price objective on shares of Mednax in a report on Tuesday, October 3rd. Finally, Robert W. Baird restated a “hold” rating and issued a $47.00 price objective on shares of Mednax in a report on Sunday, September 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $55.44.

In related news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Earnings History for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.